Hartmut Rehwinkel

This inventor holds 53 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Anti-Cancer Compounds (CPC class C07D). Top assignees: Schering Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Bayer Schering Pharma Ag. Active years: 1992-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hartmut Rehwinkel. Retrieved from https://idiyas.com/inventor/hartmut-rehwinkel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 10)

% Patents Active = 32.1

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 18 (Patent Applications = 19)

Average Co-Inventor Count = 7.2

ph-index = 8

Forward Citations = 212(Granted Patents)

Forward Citations (Not Self Cited) = 154(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

22 out of 1,409

Schering Aktiengesellschaft

patents

16 out of 387

Bayer Pharma Aktiengesellschaft

patents

10 out of 192

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

patents

where one patent can have more than one assignee

Years Active: 1992-2021

Loading Chart...

Areas of Expertise:

mIDH1 Inhibitors

Akt Kinase Inhibitors

Anti-Inflammatory Agents

Benzimidazol-2-Amines

Indazoles Derivatives

Tetrahydronaphthalene Derivatives

Quinoline Derivatives

Pyrimido Indazoles

Pyrazolopyrimidines

Benzoxazine Derivatives

Glucocorticoid Modulators

Trifluoro-2-Hydroxy Compounds

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10919862 - Fused imidazoles as mIDH1 inhibitors (2021-02-16),

2. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

3. 10138226 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-11-27),

4. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

5. RE47047 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents (2018-09-17),

6. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

7. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

8. 9738632 - Phenyl and benzodioxinyl substituted indazoles derivatives (2017-08-22),

9. 9604989 - Imidazopyridazines as Akt kinase inhibitors (2017-03-28),

10. 9512110 - Phenyl and benzodioxinyl substituted indazoles derivatives (2016-12-06),

11. 9370517 - Substituted pyrazolopyrimidines as Akt kinase inhibitors (2016-06-21),

12. 9260435 - Substituted imidazopyrazines as Akt kinase inhibitors (2016-02-16),

13. 9206185 - Imidazopyridazines as Akt kinase inhibitors (2015-12-08),

14. 8987286 - Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway (2015-03-24),

15. 8987273 - Substituted imidazo[1,2-B]pyridazines (2015-03-24),

Certainly! Here is the article about inventor Hartmut Rehwinkel:

Title: Unveiling the Innovative Mind of Hartmut Rehwinkel

Introduction:

Hartmut Rehwinkel, a distinguished inventor hailing from Berlin, Germany, has left a significant mark in the domain of pharmaceutical innovations with his prolific work and numerous patents.

Latest Patents:

Rehwinkel's latest patents showcase his groundbreaking research in the field of oncology. His inventions, namely "Fused imidazoles as mIDH1 inhibitors" and "Benzimidazol-2-amines as mIDH1 inhibitors," present novel compounds and methods for the treatment of neoplasms, emphasizing his commitment to advancing medical science.

Career Highlights:

Throughout his career, Rehwinkel has amassed an impressive portfolio of 53 patents, demonstrating his expertise and dedication to driving innovation in the pharmaceutical industry. He has made significant contributions while working at renowned companies such as Schering Aktiengesellschaft and Bayer Pharma Aktiengesellschaft.

Collaborations:

In his journey of innovation, Rehwinkel has collaborated with esteemed colleagues such as Markus Berger and Stefan Jaroch, fostering a culture of teamwork and knowledge sharing to push the boundaries of scientific discovery.

Conclusion:

In conclusion, Hartmut Rehwinkel stands as a shining example of an inventive mind shaping the landscape of pharmaceutical advancements. His relentless pursuit of excellence and passion for innovation continue to inspire and pave the way for future breakthroughs in the realm of medical research.

If you have any more specific requests or need further information, feel free to ask!

Profile summary based on public USPTO records.